MRNA vs VRTX Comparison: AI Score, Valuation, Performance and Upside
Compare Moderna and Vertex by platform technology durability, COVID vaccine revenue decline vs CF monopoly stability, pipeline breadth, cash runway, and which biotech approach offers better long-term investment returns.
Use this Moderna vs Vertex comparison to evaluate the key differences across valuation, growth, profitability, and risk before making an investment decision.
VRTX holds the edge across 4 of 5 key metrics in this comparison. MRNA has delivered stronger 1-year price return (+58.98% vs +1.08%), though VRTX has the better forward P/E setup (22.68x vs -15.03x for MRNA). On fundamentals, MRNA is growing revenue faster (260.20%), while VRTX maintains the higher operating margin (38.13%) — a classic growth-versus-profitability split. Analyst consensus implies meaningfully more upside for VRTX (+14.16%) than for MRNA (-21.93%).
| Metric | MRNA | VRTX |
|---|---|---|
| AI score | 44.5 | 51.0 |
| AI rank | #801 | #447 |
| Latest close | $54.07 | $477.36 |
| 1M return | -10.51% | +0.45% |
| 6M return | +11.00% | +1.91% |
| 1Y return | +58.98% | +1.08% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | MRNA | VRTX |
|---|---|---|
| 1Y ago | $15.83K (+58.3%) started 2025-07-25 | $10.16K (+1.6%) started 2025-07-25 |
| 5Y ago | $1.61K (-83.9%) started 2021-07-26 | $24K (+140.0%) started 2021-07-26 |
| 10Y ago | $29.07K (+190.7%) started 2018-12-07 | $49.84K (+398.4%) started 2016-07-25 |
Hypothetical — past performance does not guarantee future results.
| Metric | MRNA | VRTX |
|---|---|---|
| Market cap | $24.53B | $123.26B |
| Trailing P/E | N/A | 28.82 |
| Forward P/E | -15.03 | 22.68 |
| Price/Sales | N/A | 10.42 |
| EV/Revenue | 9.27 | 9.66 |
| Analyst target | $48.26 | $554.43 |
| Target upside | -21.93% | +14.16% |
| Metric | MRNA | VRTX |
|---|---|---|
| Revenue growth | 260.20% | 7.80% |
| Earnings growth | N/A | 61.40% |
| EPS growth | N/A | +61.40% |
| FCF margin | -0.90% | +22.78% |
| Operating margin | -131.10% | 38.13% |
| Profit margin | -143.55% | 35.51% |
| ROIC proxy | -36.56% | 24.20% |
| Return on equity | -36.56% | 24.20% |
| Dividend yield | N/A | N/A |
| Beta | 0.94 | 0.29 |
| Debt/equity | 17.52 | 10.26 |
| Current ratio | 2.41 | 3.02 |
| Quick ratio | 2.23 | 2.38 |
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | MRNA | VRTX |
|---|---|---|---|
| 1Y | Growth | +58.33% | +1.64% |
| CAGR | +58.55% | +1.65% | |
| Sharpe ratio | 0.94 | 0.10 | |
| Max drawdown | 34.52% | 22.39% | |
| Max daily drop | 10.83% | 20.60% | |
| Max wkly drop | 19.17% | 20.71% | |
| 5Y | Growth | -83.90% | +139.96% |
| CAGR | -30.62% | +19.15% | |
| Sharpe ratio | -0.28 | 0.60 | |
| Max drawdown | 95.38% | 29.07% | |
| Max daily drop | 21.01% | 20.60% | |
| Max wkly drop | 33.81% | 20.71% | |
| 10Y | Growth | +190.70% | +398.44% |
| CAGR | +15.01% | +17.43% | |
| Sharpe ratio | 0.49 | 0.52 | |
| Max drawdown | 95.38% | 41.60% | |
| Max daily drop | 21.01% | 20.70% | |
| Max wkly drop | 33.81% | 22.29% |
| Category | MRNA | VRTX |
|---|---|---|
| Company | MRNA | VRTX |
| Sector | Healthcare | Healthcare |
| Industry | N/A | Biotechnology |
| Core business | N/A | N/A |
| Investor focus | N/A | N/A |
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.